Vaccination against Pneumococcal Infections of High-Risk People: Pharmacoeconomic Aspects
Relevance. Vaccination of people at high risk against pneumococcal infection with a 13-valent conjugate vaccine (PCV13) can significantly reduce the corresponding incidence and mortality.The aim of the work was to assess the pharmacoeconomic aspects of vaccination of 65 year olds with a high risk of...
Saved in:
| Main Authors: | A. V. Rudakova, S. M. Kharit, Yu. V. Lobzin |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Numikom LLC
2020-01-01
|
| Series: | Эпидемиология и вакцинопрофилактика |
| Subjects: | |
| Online Access: | https://www.epidemvac.ru/jour/article/view/863 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
VACCINATION AGAINST PNEUMOCOCCAL INFECTIONS IN RUSSIAN FEDERATION: SOCIAL AND PHARMACOECONOMIC ASPECTS
by: A. V. Rudakova, et al.
Published: (2018-10-01) -
Vaccine Prevention of Pneumococcal Infection in Children
by: Alexander A. Baranov, et al.
Published: (2018-07-01) -
Cost-effectiveness of vaccination against pneumococcal infection of adults at risk within the federal and regional programs
by: A. V. Rudakova, et al.
Published: (2019-12-01) -
Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United States
by: Zinan Yi, et al.
Published: (2024-11-01) -
Efficacy of conjugate vaccines in pneumococcal infection prevention
by: A. L. Perova, et al.
Published: (2014-09-01)